Amarin (AMRN) “announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRN:
- Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk
- Amarin Earnings Call: Cost Cuts, Cash, and Crosswinds
- Amarin highlights recent data published on REDUCE-IT study
- Amarin reports Q4 non-GAAP EPS 1c vs. (2c) last year
- Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities